Hisamitsu Pharmaceutical Co., Inc. (4530.T)

3,636.00 -28.00 (-0.76%) At close: 03:15PM JST

Hisamitsu Pharmaceutical Co., Inc.

Tashirodaikan-machi 408
Tosu 841-0017
Japan
81 3 5293 1720
https://www.global.hisamitsu

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 2,759

Description

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to Asia, the United States of America, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.

Corporate governance

Hisamitsu Pharmaceutical Co., Inc.’s ISS governance QualityScore as of 1 June 2024 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder rights: 9; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.